Open Forum Infectious Diseases · 2021 · 32 citations · 17 references
Life SciencesInfectious DiseasesPharmacotherapyAntimicrobial PharmacotherapyAntimicrobial ResistanceMedical MicrobiologyAntibiotic ResistanceAntimicrobial TherapyBacterial InfectionsMultidrug ResistanceResistance In Gram-negative BacteriaResistance In Gram-positive BacteriaBacterial Multidrug ResistanceMulticenter TrialsMultidrug-resistant Gram-negative BacteriaMultidrug-resistant Infection TreatmentMultidrug-resistant OrganismsMultidrug-resistant PathogensPseudomonas Aeruginosa Infection TreatmentPseudomonas Aeruginosa Resistance
Abstract A multicenter case series of 21 patients were treated with imipenem-cilastatin-relebactam. There were mixed infection sources, with pulmonary infections (11/21,52%) composing the majority. The primary pathogen was Pseudomonas aeruginosa (16/21, 76%), and 15/16 (94%) isolates were multidrug-resistant. Thirty-day survival occurred in 14/21 (67%) patients. Two patients experienced adverse effects.
17
Paul A. Harris, Robert Taylor, Robert J. Thielke et al. · Journal of Biomedical Informatics · 2008 · 51.7K citations · Full text
Anna-Pelagia Magiorakos, Arjun Srinivasan, Roberta B. Carey et al. · Clinical Microbiology and Infection · 2011 · 14K citations
William A. Knaus, Elizabeth A. Draper, Douglas P. Wagner et al. · Critical Care Medicine · 1985 · 13.7K citations
Medicine, Internal Medicine, Clinical Classification Systems +16
A method for estimating the probability of adverse drug reactions
C. A. Naranjo, U. Busto, Edward M. Sellers et al. · Clinical Pharmacology & Therapeutics · 1981 · 11.6K citations